Mankind Pharma Ltd Hits Intraday High with 3.93% Surge on 3 Feb 2026

Intraday Price Movement and Trading Action

The stock opened with a gap-up of 2.15%, signalling early bullish sentiment among traders. Throughout the session, Mankind Pharma Ltd maintained upward momentum, touching a peak of Rs 2,152.5, which represents a 4.13% gain from its prior close. This intraday high was accompanied by a day change of 3.93%, underscoring strong buying interest during the trading day.

Notably, the stock reversed its trend after two consecutive days of decline, marking a positive shift in price action. It outperformed the Pharmaceuticals & Biotechnology sector, which itself gained 2.87%, by 1.07%, and also surpassed the Sensex’s 2.89% rise for the day. This relative strength highlights Mankind Pharma Ltd’s resilience amid broader market fluctuations.

Technical Indicators and Moving Averages

From a technical perspective, the stock is trading above its 5-day moving average, indicating short-term strength. However, it remains below its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting that longer-term momentum has yet to fully recover. The stock is currently 4.58% away from its 52-week low of Rs 2,050, indicating it is trading near the lower end of its annual price range.

This positioning near the 52-week low, combined with the recent intraday surge, may reflect a short-term correction or consolidation phase within a broader downtrend, as evidenced by the stock’s longer-term performance metrics.

Market Context and Sector Performance

The broader market environment on 3 Feb 2026 was characterised by volatility. The Sensex opened sharply higher by 3,656.74 points but subsequently lost momentum, falling by 1,277.33 points to trade at 84,045.87, a net gain of 2.91% for the day. Despite this pullback, the Sensex remains 2.51% below its 52-week high of 86,159.02.

Within this context, mega-cap stocks led the market rally, while the Pharmaceuticals & Biotechnology sector recorded a solid gain of 2.87%. Mankind Pharma Ltd’s outperformance relative to both its sector and the Sensex highlights its distinct trading strength amid a mixed market backdrop.

Performance Trends Over Various Timeframes

Examining Mankind Pharma Ltd’s performance over multiple periods reveals a mixed picture. The stock has outperformed the Sensex over the past day and week, with gains of 4.11% and 2.76% respectively, compared to the Sensex’s 2.89% and 2.65%. However, over longer durations, the stock has lagged behind the benchmark index. It recorded a decline of 2.30% over the past month and a more pronounced drop of 10.40% over three months, while the Sensex posted a slight positive return of 0.05% during the same period.

Year-to-date, Mankind Pharma Ltd is down 2.02%, slightly underperforming the Sensex’s 1.40% decline. Over one year, the stock has fallen 16.71%, contrasting with the Sensex’s 8.86% gain. The stock’s three-year, five-year, and ten-year returns remain flat at 0.00%, while the Sensex has delivered substantial gains of 38.10%, 67.19%, and 246.87% respectively over these intervals.

Mojo Score and Rating Update

Mankind Pharma Ltd currently holds a Mojo Score of 38.0, with a Mojo Grade of Sell. This represents a downgrade from its previous Hold rating, effective from 19 Nov 2025. The company’s Market Cap Grade stands at 1, indicating a relatively modest market capitalisation within its sector. These metrics provide a quantitative assessment of the stock’s quality and market standing as of the latest evaluation.

Summary of Intraday Strength

In summary, Mankind Pharma Ltd’s strong intraday performance on 3 Feb 2026 was marked by a 4.13% peak gain and a 3.93% day change, outperforming both its sector and the Sensex. The stock’s recovery after two days of decline and its gap-up opening reflect renewed trading interest. Despite remaining below key longer-term moving averages, the stock’s short-term momentum is evident.

The broader market’s mixed session, with mega-cap leadership and sector gains, provides a nuanced backdrop for Mankind Pharma Ltd’s price action. The company’s recent downgrade in Mojo Grade and modest market cap grade offer additional context for its current valuation and market perception.

Trading volumes and further intraday data were not disclosed, limiting deeper analysis of liquidity and volatility during the session.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →